Physician profile
Nathan Stice
NPI 1639213044
$199,484.69
in general payments reported to CMS, 2019-2025
47 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $1,666 · 2021: $29K · 2022: $35K · 2023: $47K · 2024: $35K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $87K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $2,791 · Travel and Lodging: $1,176 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $86,531.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,600.00 |
| Food and Beverage | $2,790.51 |
| Travel and Lodging | $1,176.33 |
| Education | $230.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $136,894.96 | 2021-2025 | Nexplanon, Jada System |
| Merck Sharp & Dohme LLC | $34,999.73 | 2019-2021 | |
| Astellas Pharma US INC | $22,787.20 | 2019-2025 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $994.92 | 2020-2024 | Ova1 |
| Abbvie INC. | $593.95 | 2019-2025 | Orilissa, Lo Loestrin Fe |
| Allergan, INC. | $372.66 | 2019 | |
| Mayne Pharma Commercial LLC | $267.81 | 2021-2023 | |
| Shield Therapeutics INC | $219.94 | 2023-2025 | Accrufer |
| Axonics, INC. | $174.76 | 2021-2023 | Bulkamid, Axonics |
| Biogen, INC. | $170.26 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $168.71 | 2019-2024 | Injectafer |
| Amgen INC. | $163.51 | 2019-2020 | |
| Pfizer INC. | $126.08 | 2022-2025 | |
| Exeltis, USA INC. | $125.35 | 2021-2025 | Slynd |
| Novo Nordisk INC | $112.50 | 2019-2023 | Wegovy, Saxenda |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Stice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.